• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

TG Therapeutics Inc

+ Add to Watchlist

NKB2:GR

6.053 EUR 0.086 1.40%

As of 02:00:09 ET on 08/22/2014.

Snapshot for TG Therapeutics Inc (NKB2)

Open: 6.053 Day's Range: 6.053 - 6.053 Volume: 0
Previous Close: 6.139 52wk Range: 2.296 - 8.115 1-Yr Rtn: -

Stock Chart for NKB2

No chart data available.
  • NKB2:GR 6.053
  • 1D
  • 1M
  • 1Y
6.139
Interactive NKB2 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NKB2

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -1.2820
Est. PEG Ratio -
Market Cap (M EUR) 230.74
Shares Outstanding (M) 38.12
30 Day Average Volume 204
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/11/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NKB2

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for NKB2

TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies, specifically, relapsed and refractory non-Hodgkins lymphoma.

Michael S Weiss "Mike"Chairman/Interim Pres & CEOSean A PowerCFO/Treasurer/Secretary
Jenna BoscoDirector:Investor Relations
More Company Profile & Key Executives for NKB2

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil